Sharma Veerta, Sharma Prateek, Singh Thakur Gurjeet
Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
J Neural Transm (Vienna). 2025 May 5. doi: 10.1007/s00702-025-02932-0.
Neuropsychiatric disorders such as bipolar disorder, migraine, major depressive disorder, epilepsy, attention-deficit/hyperactivity disorder, autism spectrum disorder and schizophrenia, are a huge burden on global health, impacting millions of individuals worldwide and posing significant barriers to effective treatment. Despite advancements in medication and psychotherapy, many patients continue to suffer from severe symptoms and receive little alleviation. All of these conditions are quite frequent, yet they affect people in a way that is exceedingly detrimental. The increasing evidence suggests the connection between these disorders and inflammation. Therefore, the use of anti-inflammatory agents, namely cyclooxygenase-2 (COX-2) inhibitors, offers a new approach to prevent and treat neuropsychiatric disorders. This review discusses about the COX pathway and the role of COX-2 in the neuroinflammation. Furthermore, this review highlights the COX-2 inhibitors as a promising therapeutic agent in these neuropsychiatric disorders, however, further studies are required to assess appropriate illness stage-related indication.
双相情感障碍、偏头痛、重度抑郁症、癫痫、注意力缺陷多动障碍、自闭症谱系障碍和精神分裂症等神经精神疾病给全球健康带来了巨大负担，影响着全球数百万人，并对有效治疗构成重大障碍。尽管药物治疗和心理治疗取得了进展，但许多患者仍遭受严重症状的折磨，症状缓解甚微。所有这些病症都相当常见，但它们对人的影响极其有害。越来越多的证据表明这些疾病与炎症之间存在关联。因此，使用抗炎药物，即环氧化酶-2（COX-2）抑制剂，为预防和治疗神经精神疾病提供了一种新方法。 本综述讨论了COX途径以及COX-2在神经炎症中的作用。此外，本综述强调COX-2抑制剂作为这些神经精神疾病中有前景的治疗药物，然而，需要进一步研究以评估与疾病阶段相关的合适适应症。
